Table 2 Experiment models for exploring the roles of TLR9 in cardiometabolic disorders

Tlr9^-/-

(B6.129P2^-Tlr9tmAki)

HFD, 60 kcal% fat

12 weeks

-

-

promotive

[10]

 C57BL/6

12 weeks

-

iODN2088 for 12 weeks

Tlr9^+/+ bone marrow in Tlr9^-/-

(B6.129P2^-Tlr9tmAki)

12 weeks

-

-

Tlr9^-/-

(C57BL/6J^-Tlr9M7Btlr)

HFD, 60 kcal% fat

15 weeks

-

-

promotive

[11]

 C57BL/6

10 weeks

-

IRS954 for 3 weeks

 C57BL/6J

Normal chow diet

8 days

CpG-ODN2395 for 8 days

-

 C57BL/6J

HFD, 40 kcal% fat

12 weeks

-

-

-

[12]

ob/ob

Standard chow diet

12 weeks

-

-

Tlr9^-/-

(B6.129P2^-Tlr9tmAki)

HFD, 60 kcal% fat

8-10 weeks

-

-

protective

[13]

Tlr9^-/-Apoe^-/-

(C57BL/6 background)

WTD, 21% fat, 0.2% cholesterol

+Ang II-infusion

for 4 weeks

12 weeks

-

-

promotive

[19]

Tlr9^-/-Apoe^-/-

(C57BL/6 background)

12 weeks

-

iODN2088 for 4 weeks

Tlr9^+/+ bone marrow in Tlr9^-/-Apoe^-/-

(C57BL/6 background)

12 weeks

-

-

Apoe*3Leiden

transgenic mice

WTD

+ cuff placement

for 2 weeks

5 weeks

-

TLR7/9 dual antagonist for 2 weeks

promotive

[22]

Apoe^-/-

 (C57BL/6 background)

Cholesterol rich diet, 21% fat and 1.25% cholesterol

8 weeks

CpG-ODN1826 for 7 weeks

-

promotive

[26]

Apoe^-/-

HFD, 21% fat and 0.15% cholesterol

6 weeks

CpG-ODN1585 for 5 weeks

-

promotive

[20]

Tlr9^-/-Apoe^-/-

(C57BL/6 background)

HFD, 21% fat and 0.15% cholesterol

12 weeks

-

-

protective

[27]

Apoe^-/-

(C57BL/6 background)

8 weeks

CpG-ODN1668 for 8 weeks

-